Key Takeaways
- On April 14, two board members at Conagra collectively acquired 42,500 shares, investing approximately $609,000 when the stock traded near its yearly bottom.
- Shares of CAG have declined 17% during 2026, pressured by declining sales volumes, shrinking margins, and reduced guidance for the fiscal year.
- The company’s third-quarter results disappointed with earnings per share of $0.39 (versus expectations of $0.40) and a 1.9% year-over-year revenue decline.
- This week, Morgan Stanley reduced its price objective to $15 from $17 while maintaining an “equal weight” stance.
- Wall Street consensus stands at “Reduce” with a mean price target of $15.80, reflecting 1 Buy rating, 13 Hold ratings, and 4 Sell ratings.
In a show of confidence, two members of Conagra’s board recently made substantial stock purchases. Richard H. Lenny, a director at the company, acquired 25,000 shares at $14.34 apiece on April 14, totaling an investment of $358,500. Fellow director John J. Mulligan followed suit the same day, purchasing 17,500 shares at $14.31 each for a total of $250,425.
The two transactions together represent approximately $609,000 in capital deployment, executed when shares were hovering just above the 12-month low of $14.04. Notably, Mulligan’s purchase boosted his stake by an impressive 542%. Following his acquisition, Lenny’s total holdings reached 229,340 units, currently valued at approximately $3.3 million.
The context surrounding these purchases is significant. The stock’s recent slide accelerated on April 9 following a BNP Paribas downgrade from Outperform to Neutral, accompanied by a price target reduction from $19 to $16. Shares breached the $16 level that very session.
The pressure intensified shortly after. When Conagra announced John Brase as its incoming CEO and president on April 13, Jefferies noted that the new executive would inherit “high leverage, ongoing inflationary pressures, and margin compression.”
Disappointing Quarterly Performance Compounds Concerns
Earlier in April, Conagra unveiled its fiscal third-quarter financial results, which fell short of Wall Street’s expectations. The packaged foods giant delivered earnings of $0.39 per share, one cent below the anticipated $0.40. While revenue of $2.79 billion edged past the $2.76 billion forecast, it offered little consolation.
The modest revenue beat masked deeper troubles. Sales declined 1.9% compared to the prior-year period, and earnings per share tumbled from $0.51 in last year’s third quarter—a significant deterioration. Management also lowered its full-year outlook, citing challenging macroeconomic conditions and unrelenting inflationary headwinds.
Year-to-date, the stock has surrendered 17% of its value, while the broader S&P 500 has advanced 4.2% during the identical timeframe.
Wall Street Remains Skeptical
Analyst sentiment toward the stock remains decidedly lukewarm. Morgan Stanley this week trimmed its price target on CAG to $15 from $17, though it retained an “equal weight” rating. That new target suggests merely 3.6% potential upside from Wednesday’s closing level.
The downward revisions extend beyond Morgan Stanley. JPMorgan reduced its target from $19 to $17 in March. Both TD Cowen and Deutsche Bank moved to a $14 price objective. Stifel made a similar cut to $15 this week.
According to MarketBeat’s current tally, CAG carries 1 Buy recommendation, 13 Hold ratings, and 4 Sell ratings, producing an average price target of $15.80 and an overall “Reduce” rating.
On Thursday, CAG shares opened at $14.49. The stock’s 50-day moving average stands at $16.75, while the 200-day moving average rests at $17.38—both considerably above current trading levels.
One metric worth highlighting: CAG’s dividend yield currently sits around 9%, making it the highest-yielding stock in the entire S&P 500. For context, the average dividend yield among S&P 500 payers is just 2.3%.
Institutional ownership accounts for 83.75% of outstanding shares. A handful of smaller investment funds have expanded their positions in recent quarters, though these additions have been relatively minor.
